Gedeon/Actavis's new cariprazine data enough in schizophrenia?
This article was originally published in Scrip
Executive Summary
Gedeon Richter and Actavis's novel antipsychotic cariprazine has shown positive top-line Phase III results in preventing relapse in patients with schizophrenia, but analysts doubt that they will be enough to propel decent sales of the product in the presence of generic competition.